REMIFENTANIL HYDROCHLORIDE FOR INJECTION 2 MG
REMIFENTANIL (REMIFENTANIL HYDROCHLORIDE) : 2 MG · DIN 02366479 · STERIMAX INC
Health Canada status: MARKETED
What is REMIFENTANIL HYDROCHLORIDE FOR INJECTION?
REMIFENTANIL HYDROCHLORIDE FOR INJECTION 2 MG contains REMIFENTANIL (REMIFENTANIL HYDROCHLORIDE) : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02366479, held by STERIMAX INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 29-Sep-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is REMIFENTANIL HYDROCHLORIDE FOR INJECTION used for?
Analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures in adults. Not for as-needed (prn) use.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02366479 |
|---|---|
| Brand name | REMIFENTANIL HYDROCHLORIDE FOR INJECTION |
| Generic / active ingredient | REMIFENTANIL (REMIFENTANIL HYDROCHLORIDE) : 2 MG |
| Manufacturer | STERIMAX INC |
| Strength | 2 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N01AH06 REMIFENTANIL |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Sep-2011 |
| Original market date | 2011-09-29 00:00:00 |
How is it administered?
IV administration only. Continuous infusion via device. Induction: 0.5 to 1 mcg/kg (over 30-60s). Maintenance: 0.05 to 2 mcg/kg/min. Requires individualized titration.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. (Note: General lyophilized powder storage; specific range inferred from standard practice if not explicitly in summary).
How is it supplied?
1 mg, 2 mg, 5 mg vials.
Contraindications
Epidural/intrathecal use; hypersensitivity to remifentanil or opioids; GI obstruction; acute abdomen; asthma; respiratory depression; acute alcoholism; severe CNS depression; head injury; MAOIs.
Warnings and precautions
Risk of addiction, abuse, misuse. Life-threatening respiratory depression. Muscle rigidity (dose-related). Not for sole use in anesthesia. Rapid offset of effect upon discontinuation.
What can be used instead?
Other Canadian products sharing ATC code N01AH06 REMIFENTANIL. 2 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| REMIFENTANIL HYDROCHLORIDE FOR INJECTION | 1 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02366460 |
| REMIFENTANIL FOR INJECTION | 1 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02344424 |
| REMIFENTANIL FOR INJECTION | 1 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02393204 |
| REMIFENTANIL FOR INJECTION | 2 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02393212 |
| REMIFENTANIL FOR INJECTION | 2 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02344432 |
| REMIFENTANIL HYDROCHLORIDE FOR INJECTION | 5 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | DIN 02366495 |
| ULTIVA | 1 MG | POWDER FOR SOLUTION | ABBVIE CORPORATION | CANCELLED POST MARKET | DIN 02230409 |
| ULTIVA | 2 MG | POWDER FOR SOLUTION | ABBVIE CORPORATION | CANCELLED POST MARKET | DIN 02230410 |
| ULTIVA | 5 MG | POWDER FOR SOLUTION | ABBVIE CORPORATION | CANCELLED POST MARKET | DIN 02230411 |
Who else supplies REMIFENTANIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. REMIFENTANIL appears in 50 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for REMIFENTANIL HYDROCHLORIDE FOR INJECTION
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.